

Retraction: Abstract 408: ACP-196, An Orally Bioavailable Covalent Selective Inhibitor of Btk, Modulates the Innate Tumor Microenvironment, Exhibits Antitumor Efficacy and Enhances Gemcitabine Activity in Pancreatic Cancer



The above-referenced Abstract, which was published in the August 2015 *Cancer Research* supplement (1), is being retracted at the request of Acerta Pharma. The Abstract was included in a retrospective review conducted by the sponsor as part of an assessment of research activities. The sponsor worked with several of the authors and the collaborating academic research institute to establish the source of data that contributed to the information in the Abstract. The review demonstrated that no source of the data could be identified to support the statements in the second paragraph of the Abstract. As the source of these data cannot be located, it was determined that these data were not reliable and Acerta Pharma requests retraction of the Abstract.

The authors have agreed to this Retraction.

Reference

1. Lannutti BJ, Gulrajani M, Krantz F, Bibikova E, Covey T, Jessen K, et al. ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia, PA. Philadelphia, PA: AACR; 2015. Abstract nr 408.

Published online September 1, 2017.

doi: 10.1158/0008-5472.CAN-17-2154

©2017 American Association for Cancer Research.